Latest NeuroSense Therapeutics News & Updates

See the latest news and media coverage for NeuroSense. We track all announcements, press releases, and industry mentions in real time, all in one place.

NeuroSense Therapeutics (NeuroSense)

Clinical-stage biotech developing neurodegenerative disease treatments

neurosense-tx.com

Headquarters: Cambridge, United States
Founded year: 2017
Company type: Public company
Number of employees: 25–50

Last updated Today

Latest news about NeuroSense Therapeutics (NeuroSense)

In short: NeuroSense Therapeutics advanced its ALS drug PrimeC toward Phase 3 trials and regulatory approval while securing global patents and financing.

Company announcements

June 9 NeuroSense

NeuroSense receives Japanese patent for PrimeC composition

The patent covers its ALS drug candidate's formulation and extends protection through 2042, strengthening its global IP estate.

April 28 NeuroSense

NeuroSense announces pricing of insider-led PIPE financing

The $600,000 private placement involves 750,000 shares at $0.80 each, led by CEO and CFO. Proceeds fund general corporate purposes.

April 6 NeuroSense

NeuroSense receives Brazilian patent for PrimeC

The patent protects the composition through October 2042, following U.S. and Australian grants, strengthening global IP for ALS and Alzheimer's treatments.

April 3 NeuroSense

NeuroSense Therapeutics receives Nasdaq notifications

The Company is not in compliance with minimum bid price and market value requirements. Nasdaq grants until September 29, 2026, to regain compliance. Trading continues unaffected.

Media coverage

June 9 ALS News Today

Neurosense, Health Canada discuss approval path for PrimeC

The FDA, after providing positive feedback on the trial's design, cleared Neurosense to initiate PARAGON late last year. The study expects to enroll about 300...

April 28 The Globe and Mail

NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price

Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

April 25 The Globe and Mail

NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones

On April 24, 2026, NeuroSense Therapeutics announced that Chief Medical Officer Dr. Ferenc Tracik will step down from his role, effective April 27, 2026, and...

April 11 The Globe and Mail

NeuroSense Therapeutics Posts 2025 Results as PrimeC Advances Toward Phase 3 ALS Trial

Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

Never miss news about NeuroSense

Track NeuroSense and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

NeuroSense competitors & trending companies

Browse news for competitors to NeuroSense and other trending companies.